Point of Care Diagnostics Market by Product (Glucose, Infectious Disease, Pregnancy), Purchase Mode, Technology (Biochemistry, MDx ), Sample, End User - Global Forecast to 2029
세계의 POC(Point of Care) 진단 시장 규모는 2024년 150억 5,000만 달러에서 2029년까지 226억 3,000만 달러에 달할 것으로 추정되며, CAGR로 8.5%의 성장이 전망됩니다.
POC 테스트의 주요 촉진요인 중 하나는 정부의 구상과 자금 지원입니다. 전 세계에서 정부는 이러한 기술이 의료 접근성을 개선하고 비용을 낮추며 환자 치료 결과를 개선하는 데 필수적이라고 보고 있습니다. 많은 정부들은 POC 테스트 솔루션의 개발 및 채택에 초점을 맞추기 위해 규제적 인센티브와 함께 보조금 지급 및 재정적 지원을 제공합니다. 적절한 의료시설이 부족한 개발도상국에서는 정부가 POC 기기를 많이 사용하도록 장려하고, 소외된 계층에 대한 검사를 분산시키고 있습니다. 이러한 지원책은 POC 진단의 채택을 가속화하여 진단 기업에게 새로운 시장 기회를 제공합니다.
| 조사 범위 |
| 조사 대상연도 |
2022-2029년 |
| 기준연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
달러 |
| 부문 |
제품, 구입 방식, 기술, 샘플, 최종사용자 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가 |
"제품별로는 감염병 검사 제품 부문이 시장에서 가장 빠른 성장률을 보일 것으로 예상됩니다."
감염성 질환 검사 제품은 전 세계에서 감염성 질환의 높은 유병률로 인해 현장 진단 시장에서 가장 빠르게 성장할 것으로 예상됩니다. 지역 진료소 및 농촌 보건소를 위한 빠르고 정확하며 분산된 의료 진단 솔루션에 대한 수요가 증가하면서 이 부문 수요를 촉진하고 있습니다. 더 빠른 분자진단 및 향상된 면역 분석 플랫폼을 포함한 개선된 기술은 POC 테스트의 속도와 정확성을 향상시켜 효율성을 높입니다. 또한 공중 보건에 대한 노력이 증가하고 감염성 질환에 대한 POC 솔루션에 대한 인식이 높아짐에 따라 이러한 제품의 채택이 크게 증가하고 있습니다.
"샘플별로는 혈액 샘플 부문이 예측 기간 중 시장에서 가장 큰 시장 점유율을 차지할 것입니다."
혈액 샘플은 현장 진단 시장에서 가장 큰 시장 점유율을 차지합니다. 혈액 샘플의 중요한 역할은 당뇨병, 심혈관 질환, 감염성 질환, 대사이상 등 다양한 질병을 감지하는 데 있습니다. 혈액 기반 검사는 정확하고 신뢰성이 높으며, 결과가 나오기까지 시간이 오래 걸리는 것으로 알려져 있습니다. 이러한 이유로 임상 및 병상 환경 모두에서 가장 적합한 샘플 유형입니다. 또한 혈액 기반 POC 기기의 효율성은 최소한의 시료로 정확한 결과를 얻을 수 있는 기술의 발전으로 인해 향상되고 있습니다. 또한 만성질환과 감염성 질환은 지속적으로 증가하고 있으며, 혈액 기반 검사를 필요로 하는 신속하고 편리한 진단 솔루션에 대한 수요가 증가하고 있습니다.
"아시아태평양: 가장 빠르게 성장하는 현장진단 시장"
아시아태평양은 여러 요인으로 인해 POC 시장이 크게 성장하고 있습니다. 질병의 조기 발견, 예방, 정기적인 건강 검진을 장려하는 정부의 구상은 주요 촉진요인이며, 건강 검진 보급과 적시 개입을 장려하는 여러 가지 노력이 있습니다. 이러한 노력과 지역 전반의 의료비 증가로 인해 진단 솔루션에 대한 접근성과 수요가 증가하고 있습니다. 인도와 중국 등에서는 당뇨병과 같은 만성질환이 증가하고 있으며, 신속하고 정확한 진단 장비에 대한 수요도 증가하고 있습니다. 조기 진단과 조기 관리를 통한 공중보건 향상으로 인해 이 지역에서도 POC 진단을 채택하는 의료기관이 증가하고 있습니다.
세계의 POC(Point-Of-Care)(Point of Care) 진단 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
- POC(Point of Care) 진단 시장의 개요
- POC(Point of Care) 진단 시장 : 제품별(2024년·2029년)
- POC(Point of Care) 진단 시장 : 구입 방식별(2024년·2029년)
- POC(Point of Care) 진단 시장 : 기술별(2024년·2029년)
- POC(Point of Care) 진단 시장 : 샘플별(2024년·2029년)
- POC(Point of Care) 진단 시장 : 최종사용자별(2024년·2029년)
- POC(Point of Care) 진단 시장 : 지역적 성장 기회
제5장 시장의 개요
- 서론
- 시장 역학
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 평균 판매 가격 : 제품별
- 글루코오스 모니터링 테스트 스트립의 평균 판매 가격 : 주요 기업별
- 평균 판매 가격 : 지역별
- 밸류체인 분석
- 공급망 분석
- 에코시스템 분석
- 투자와 자금조달 시나리오
- 기술 분석
- 특허 분석
- 무역 분석
- HS 코드 3822의 수입 데이터
- HS 코드 3822의 수출 데이터
- 주요 컨퍼런스와 이벤트(2025-2026년)
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- POC(Point of Care) 진단 시장에 대한 AI의 영향
- 서론
- POC(Point of Care) 진단 시장에서 AI의 시장 가능성
- AI 사용 사례
- AI를 도입하고 있는 주요 기업
- POC(Point of Care) 진단 시장에서 AI의 미래
- 규제 상황
- 사례 연구 분석
제6장 POC(Point of Care) 진단 시장 : 제품별
- 서론
- 혈당 모니터링 제품
- 심혈관대사 모니터링 제품
- 감염증 검사 제품
- 응고 모니터링 제품
- 임신·생식 검사 제품
- 종양/암마커 검사 제품
- 요검사 제품
- 콜레스테롤 검사 제품
- 혈액검사 제품
- 약물 남용 검사 제품
- 갑상선 자극 호르몬 검사 제품
- 변잠혈 검사 제품
- 기타 제품
제7장 POC(Point of Care) 진단 시장 : 구입 방식별
제8장 POC(Point of Care) 진단 시장 : 기술별
제9장 POC(Point of Care) 진단 시장 : 샘플별
- 서론
- 혈액 샘플
- 비강·인두 스왑
- 뇨샘플
- 기타 샘플
제10장 POC(Point of Care) 진단 시장 : 최종사용자별
- 서론
- 홈케어 환경, 자가 검사
- 임상 검사실
- 병원, 집중치료 센터, 구급 치료 센터
- 외래 진료 시설, 의사 진료소
- 기타 최종사용자
제11장 POC(Point of Care) 진단 시장 : 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동 및 아프리카
- GCC 국가
제12장 경쟁 구도
- 서론
- 주요 참여 기업의 전략/강점
- 매출 분석(2021-2023년)
- 시장 점유율 분석(2023년)
- 기업의 평가와 재무 지표
- 브랜드/제품의 비교
- ABBOTT
- F. HOFFMANN-LA ROCHE LTD.
- NOVA BIOMEDICAL
- 기업 평가 매트릭스 : 주요 기업(2023년)
- 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
- 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
- 경쟁 시나리오
제13장 기업 개요
- 주요 기업
- ABBOTT
- SIEMENS HEALTHINEERS AG
- F. HOFFMANN-LA ROCHE LTD
- DANAHER
- QUIDELORTHO CORPORATION
- BD
- THERMO FISHER SCIENTIFIC INC.
- BIOMERIEUX
- BIOSYNEX SA
- EKF DIAGNOSTICS HOLDINGS PLC
- TRINITY BIOTECH
- WERFEN
- NOVA BIOMEDICAL
- SEKISUI DIAGNOSTICS
- BODITECH MED INC.
- 기타 기업
- GRIFOLS, S.A.
- LIFESCAN IP HOLDINGS, LLC
- PTS DIAGNOSTICS
- EUROLYSER DIAGNOSTICA GMBH
- RESPONSE BIOMEDICAL
- ALFA SCIENTIFIC DESIGNS, INC.
- BTNX INC.
- ASCENSIA DIABETES CARE HOLDINGS AG
- FLUXERGY
- PRECISION BIOSENSOR, INC.
- ACON LABORATORIES, INC.
- MENARINI DIAGNOSTICS S.R.L
- ORASURE TECHNOLOGIES, INC.
- MANKIND PHARMA
제14장 부록
KSA
The point of care diagnostics market is estimated to reach USD 22.63 billion in 2029 from the forecasted value of USD 15.05 billion in 2024 at a CAGR of 8.5%. One of the primary reasons that will fuel POC testing is the favourable government initiatives and funding. Globally, governments consider these technologies essential in improving the accessibility of health care, bringing down costs, and enhancing outcomes for patients. Many governments also provide financial support in addition to the provision of grants with regulatory incentives to focus on the development and adoption of POC testing solutions. In developing countries with a lack of proper health care facilities, the governments encourage using POC devices abundantly, decentralizing tests for more underserved populations. Such supportive measures accelerate the adoption of POC diagnostics and thus are opening new market opportunities for diagnostic companies.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | Product, Mode of Purchase, Technology, Sample, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries |
"Infectious disease testing products segment is expected to have the fastest growth rate in the point of care diagnostics market, by product, during the forecast period."
The point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products, based on product. Infectious disease testing products are expected to witness the fastest growth in the point of care diagnostics market, mainly driven by the high prevalence of infectious diseases worldwide. The increased demand for fast, accurate, and decentralized healthcare diagnostic solutions for community clinics and rural health centers has been driving the demand in this segment. Improved technologies that include faster molecular diagnostics and enhanced immunoassay platforms enhance the speed and efficiency of accuracy in POC testing. Moreover, with an increase in public health initiatives and growing awareness of the POC solutions for infectious diseases, adoption of these products is increasing significantly.
"Blood samples segment accounted for the largest market share in the point of care diagnostics market, by sample, during the forecast period."
Based on sample, the point of care diagnostics market is bifurcated into blood samples, urine samples, nasal and oropharyngeal swabs, and other samples. The largest market share is held by blood samples in the point of care diagnostics market. Their critical role lies in detecting the broad spectrum of conditions such as diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and offer have high turnaround times for results. Because of this reason, these are the most opted sample type for both clinical and near-patient environments. Also, efficiency in blood-based POC devices has been enhanced by the technological advancements which result in accurate results with minimum sample volumes. Additionally, chronic and infectious diseases continue to be on rise, which is accompanied by a high demand for rapid and convenient diagnostic solutions requiring blood-based tests, which has helped maintain the dominance of blood samples in this market.
"Asia Pacific: The fastest-growing market for point of care diagnostics"
The worldwide market for point of care diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the point of care diagnostics market due to several factors. Government efforts to promote early disease detection, prevention, and regular health check-ups is a key driver, with a number of initiatives that encourage widespread health screening and timely intervention. These efforts, coupled with the rising healthcare expenditure across the region, have increased the accessibility and demand for diagnostic solutions. The increasing numbers of chronic conditions, such as diabetes in countries such as India and China have also increased the demand for fast and accurate diagnostic equipment. Improving public health results by early diagnosis and management is enabling more healthcare systems to become involved in adopting POC diagnostics in this region.
The break-up of the profile of primary participants in the point of care diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Other- 4%
The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMerieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), Boditech Med Inc. (South Korea), Grifols, S.A. (Spain), LifeScan IP Holdings, LLC (US), PTS Diagnostics (US), Eurolyser Diagnostica GmbH (Austria), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), BTNX Inc. (Canada), Ascensia Diabetes Care Holdings AG (Switzerland), Fluxergy (US), Precision Biosensor, Inc. (South Korea), ACON Laboratories, Inc. (US), Menarini Diagnostics s.r.l (Italy), OraSure Technologies, Inc. (US), and Mankind Pharma (India) .
Research Coverage:
This research report categorizes the point of care diagnostics market by product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the point of care diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the point of care diagnostics market. Competitive analysis of upcoming startups in the point of care diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall point of care diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing incidence of infectious disease, increasing prevalence of chronic diseases, favourable government initiatives for point of care testing, and rising number of waived tests), opportunities (Increasing growth potential in emerging markets, rising inclination toward decentralized healthcare system, booming healthcare spending worldwide), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Inadequate standardization with centralized lab methods and premium pricing of novel platforms) influencing the growth of the point of care diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the point of care diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the point of care diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point of care diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), QuidelOrtho Corporation (US), and Danaher (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
- 2.2.1.1 Key secondary sources
- 2.2.1.2 Key data from secondary sources
- 2.2.1.3 Objectives
- 2.2.2 PRIMARY DATA
- 2.2.2.1 Key primary sources
- 2.2.2.2 Key data from primary sources
- 2.2.2.3 Key industry insights
- 2.2.2.4 Breakdown of primary interviews
- 2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
- 2.3.1.1 Company revenue estimation approach
- 2.3.1.2 Presentations of companies and primary interviews
- 2.3.1.3 Growth forecast
- 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
- 2.4 DATA TRIANGULATION
- 2.5 MARKET SHARE ANALYSIS
- 2.6 RESEARCH ASSUMPTIONS
- 2.6.1 PARAMETRIC ASSUMPTIONS
- 2.6.2 GROWTH RATE ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
- 4.2 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029
- 4.3 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029
- 4.4 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
- 4.5 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029
- 4.6 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
- 4.7 POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing incidence of infectious diseases
- 5.2.1.2 Increasing prevalence of chronic diseases
- 5.2.1.3 Favorable government initiatives for point of care testing
- 5.2.1.4 Rising number of waived tests
- 5.2.2 RESTRAINTS
- 5.2.2.1 Pricing pressure on manufacturers
- 5.2.2.2 Stringent regulatory approval process for product commercialization
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing growth potential in emerging markets
- 5.2.3.2 Rising inclination toward decentralized healthcare system
- 5.2.3.3 Booming healthcare spending worldwide
- 5.2.4 CHALLENGES
- 5.2.4.1 Inadequate standardization with centralized lab methods
- 5.2.4.2 Premium pricing of novel platforms
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE, BY PRODUCT
- 5.4.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
- 5.4.3 AVERAGE SELLING PRICE, BY REGION
- 5.4.3.1 Average selling price of glucose monitoring test strips, by region
- 5.4.3.2 Average selling price of infectious disease testing products, by region
- 5.4.3.3 Average selling price of cardiometabolic monitoring products, by region
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Molecular diagnostics
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Biochemical technologies
- 5.10 PATENT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 IMPORT DATA FOR HS CODE 3822
- 5.11.2 EXPORT DATA FOR HS CODE 3822
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 BARGAINING POWER OF SUPPLIERS
- 5.13.2 BARGAINING POWER OF BUYERS
- 5.13.3 THREAT OF NEW ENTRANTS
- 5.13.4 THREAT OF SUBSTITUTES
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 KEY BUYING CRITERIA
- 5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
- 5.15.1 INTRODUCTION
- 5.15.2 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
- 5.15.3 AI USE CASES
- 5.15.4 KEY COMPANIES IMPLEMENTING AI
- 5.15.5 FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
- 5.16 REGULATORY LANDSCAPE
- 5.16.1 REGULATORY ANALYSIS
- 5.16.1.1 North America
- 5.16.1.1.1 US
- 5.16.1.1.2 Canada
- 5.16.1.2 Europe
- 5.16.1.2.1 Germany
- 5.16.1.2.2 UK
- 5.16.1.2.3 France
- 5.16.1.2.4 Italy
- 5.16.1.2.5 Spain
- 5.16.1.3 Asia Pacific
- 5.16.1.3.1 China
- 5.16.1.3.2 Japan
- 5.16.1.3.3 India
- 5.16.1.3.4 Australia
- 5.16.1.3.5 South Korea
- 5.16.1.4 Latin America
- 5.16.1.4.1 Brazil
- 5.16.1.4.2 Mexico
- 5.16.1.5 Middle East
- 5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.17 CASE STUDY ANALYSIS
- 5.17.1 CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
- 5.17.2 CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
- 5.17.3 CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS
6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 GLUCOSE MONITORING PRODUCTS
- 6.2.1 GLUCOSE MONITORING STRIPS
- 6.2.1.1 Growing trend toward preventive healthcare to drive market
- 6.2.2 GLUCOSE MONITORING METERS
- 6.2.2.1 Growing technological advancements in glucose meters to propel market
- 6.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
- 6.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
- 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
- 6.3.1 CARDIAC MARKER TESTING PRODUCTS
- 6.3.1.1 Growing government support for cardiovascular diseases to drive market
- 6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
- 6.3.2.1 Need to optimize hospital workflow to favor growth
- 6.3.3 HBA1C TESTING PRODUCTS
- 6.3.3.1 Increasing recommendations by government healthcare authorities to boost market
- 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
- 6.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
- 6.4.1.1 Influenza testing products
- 6.4.1.1.1 Need for targeted treatments to expedite growth
- 6.4.1.2 Tuberculosis
- 6.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
- 6.4.1.3 Other respiratory infection testing products
- 6.4.2 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
- 6.4.2.1 Growing rate of surgical-site infections to boost market
- 6.4.3 TROPICAL DISEASE TESTING PRODUCTS
- 6.4.3.1 Rising incidence of malaria and dengue to support growth
- 6.4.4 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
- 6.4.4.1 HIV testing products
- 6.4.4.1.1 Growing availability and awareness of testing products to boost market
- 6.4.4.2 Hepatitis testing products
- 6.4.4.2.1 Hepatitis B testing products
- 6.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
- 6.4.4.2.2 Hepatitis C testing products
- 6.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
- 6.4.4.3 Syphilis testing products
- 6.4.4.3.1 Need for early and accessible diagnosis to expedite growth
- 6.4.4.4 Human papillomavirus testing products
- 6.4.4.4.1 Rising cases of cervical cancer to promote growth
- 6.4.4.5 Chlamydia trachomatis testing products
- 6.4.4.5.1 Growing adoption of advanced techniques to drive market
- 6.4.4.6 Neisseria gonorrhea testing products
- 6.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
- 6.4.4.7 Herpes simplex virus testing products
- 6.4.4.7.1 Increasing incidence of herpes to support growth
- 6.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
- 6.4.5.1 Rising cases among hospitalized patients to boost demand
- 6.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
- 6.5 COAGULATION MONITORING PRODUCTS
- 6.5.1 PT/INR TESTING PRODUCTS
- 6.5.1.1 Increasing number of atrial fibrillation cases to accelerate growth
- 6.5.2 ACT/APTT TESTING PRODUCTS
- 6.5.2.1 Rise in surgical procedures to speed up growth
- 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
- 6.6.1 PREGNANCY TESTING PRODUCTS
- 6.6.1.1 Increasing awareness about family planning to stimulate growth
- 6.6.2 FERTILITY TESTING PRODUCTS
- 6.6.2.1 Growing infertility issues to fuel market
- 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
- 6.7.1 GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
- 6.8 URINALYSIS TESTING PRODUCTS
- 6.8.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
- 6.9 CHOLESTEROL TESTING PRODUCTS
- 6.9.1 RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
- 6.10 HEMATOLOGY TESTING PRODUCTS
- 6.10.1 INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
- 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
- 6.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
- 6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
- 6.12.1 RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
- 6.13 FECAL OCCULT TESTING PRODUCTS
- 6.13.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
- 6.14 OTHER PRODUCTS
7 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
- 7.1 INTRODUCTION
- 7.2 PRESCRIPTION-BASED TESTING PRODUCTS
- 7.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
- 7.3 OTC TESTING PRODUCTS
- 7.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
8 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
- 8.1 INTRODUCTION
- 8.2 BIOCHEMISTRY
- 8.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
- 8.3 IMMUNOASSAYS
- 8.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
- 8.4 MOLECULAR DIAGNOSTICS
- 8.4.1 RT-PCR
- 8.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
- 8.4.2 INAAT
- 8.4.2.1 Emerging new pathogens to facilitate growth
9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
- 9.1 INTRODUCTION
- 9.2 BLOOD SAMPLES
- 9.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
- 9.3 NASAL & OROPHARYNGEAL SWABS
- 9.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
- 9.4 URINE SAMPLES
- 9.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
- 9.5 OTHER SAMPLES
10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 HOME CARE SETTINGS AND SELF-TESTING
- 10.2.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
- 10.3 CLINICAL LABORATORIES
- 10.3.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
- 10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
- 10.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
- 10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
- 10.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
- 10.6 OTHER END USERS
11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
- 11.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
- 11.2.3 CANADA
- 11.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
- 11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
- 11.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
- 11.3.3 FRANCE
- 11.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
- 11.3.4 UK
- 11.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
- 11.3.5 ITALY
- 11.3.5.1 Growing burden of infectious and parasitic diseases to boost market
- 11.3.6 SPAIN
- 11.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
- 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 CHINA
- 11.4.2.1 Increasing impact of diabetes on public health to amplify growth
- 11.4.3 JAPAN
- 11.4.3.1 Booming geriatric population to stimulate growth
- 11.4.4 INDIA
- 11.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
- 11.4.5 AUSTRALIA
- 11.4.5.1 Growing research investments for next-gen point of care devices to boost market
- 11.4.6 SOUTH KOREA
- 11.4.6.1 Growing focus on innovative diagnostic products to drive market
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Increasing public initiatives in healthcare to encourage growth
- 11.5.3 MEXICO
- 11.5.3.1 Need for frequent testing for disease management to expedite growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST & AFRICA
- 11.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
- 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 11.7 GCC COUNTRIES
- 11.7.1 BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
12 COMPETITIVE LANDSCAPE
- 12.1 INTRODUCTION
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
- 12.3 REVENUE ANALYSIS, 2021-2023
- 12.4 MARKET SHARE ANALYSIS, 2023
- 12.5 COMPANY VALUATION AND FINANCIAL METRICS
- 12.6 BRAND/PRODUCT COMPARISON
- 12.6.1 ABBOTT
- 12.6.2 F. HOFFMANN-LA ROCHE LTD.
- 12.6.3 NOVA BIOMEDICAL
- 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.7.1 STARS
- 12.7.2 EMERGING LEADERS
- 12.7.3 PERVASIVE PLAYERS
- 12.7.4 PARTICIPANTS
- 12.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
- 12.7.5.1 Company footprint
- 12.7.5.2 Region footprint
- 12.7.5.3 Mode of purchase footprint
- 12.7.5.4 Technology footprint
- 12.7.5.5 Sample footprint
- 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.8.1 PROGRESSIVE COMPANIES
- 12.8.2 RESPONSIVE COMPANIES
- 12.8.3 DYNAMIC COMPANIES
- 12.8.4 STARTING BLOCKS
- 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.9.1 DETAILED LIST OF KEY STARTUPS/SMES
- 12.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
- 12.10 COMPETITIVE SCENARIO
- 12.10.1 PRODUCT LAUNCHES AND APPROVALS
- 12.10.2 DEALS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 ABBOTT
- 13.1.1.1 Business overview
- 13.1.1.2 Products offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Product launches and approvals
- 13.1.1.3.2 Deals
- 13.1.1.4 MnM view
- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 SIEMENS HEALTHINEERS AG
- 13.1.2.1 Business overview
- 13.1.2.2 Products offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Product launches and approvals
- 13.1.2.3.2 Deals
- 13.1.2.3.3 Expansions
- 13.1.2.4 MnM view
- 13.1.2.4.1 Right to win
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 F. HOFFMANN-LA ROCHE LTD
- 13.1.3.1 Business overview
- 13.1.3.2 Products offered
- 13.1.3.3 Recent developments
- 13.1.3.3.1 Product launches and approvals
- 13.1.3.3.2 Deals
- 13.1.3.3.3 Expansions
- 13.1.3.4 MnM view
- 13.1.3.4.1 Right to win
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 DANAHER
- 13.1.4.1 Business overview
- 13.1.4.2 Products offered
- 13.1.4.3 Recent developments
- 13.1.4.4 MnM view
- 13.1.4.4.1 Key strengths
- 13.1.4.4.2 Strategic choices
- 13.1.4.4.3 Weaknesses and competitive threats
- 13.1.5 QUIDELORTHO CORPORATION
- 13.1.5.1 Business overview
- 13.1.5.2 Products offered
- 13.1.5.3 Recent developments
- 13.1.5.3.1 Product launches and approvals
- 13.1.5.3.2 Deals
- 13.1.5.3.3 Expansions
- 13.1.5.4 MnM view
- 13.1.5.4.1 Right to win
- 13.1.5.4.2 Strategic choices
- 13.1.5.4.3 Weaknesses and competitive threats
- 13.1.6 BD
- 13.1.6.1 Business overview
- 13.1.6.2 Products offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Deals
- 13.1.6.3.2 Expansions
- 13.1.7 THERMO FISHER SCIENTIFIC INC.
- 13.1.7.1 Business overview
- 13.1.7.2 Products offered
- 13.1.7.3 Recent developments
- 13.1.7.3.1 Product launches and approvals
- 13.1.7.3.2 Deals
- 13.1.8 BIOMERIEUX
- 13.1.8.1 Business overview
- 13.1.8.2 Products offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Product launches and approvals
- 13.1.8.3.2 Deals
- 13.1.9 BIOSYNEX SA
- 13.1.9.1 Business overview
- 13.1.9.2 Products offered
- 13.1.9.3 Recent developments
- 13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
- 13.1.10.1 Business overview
- 13.1.10.2 Products offered
- 13.1.10.3 Recent developments
- 13.1.10.3.1 Product launches and approvals
- 13.1.10.3.2 Deals
- 13.1.10.3.3 Expansions
- 13.1.11 TRINITY BIOTECH
- 13.1.11.1 Business overview
- 13.1.11.2 Products offered
- 13.1.11.3 Recent developments
- 13.1.11.3.1 Product launches and approvals
- 13.1.11.3.2 Deals
- 13.1.12 WERFEN
- 13.1.12.1 Business overview
- 13.1.12.2 Products offered
- 13.1.12.3 Recent developments
- 13.1.12.3.1 Product launches and approvals
- 13.1.12.3.2 Deals
- 13.1.13 NOVA BIOMEDICAL
- 13.1.13.1 Business overview
- 13.1.13.2 Products offered
- 13.1.13.3 Recent developments
- 13.1.13.3.1 Product launches and approvals
- 13.1.13.3.2 Expansions
- 13.1.14 SEKISUI DIAGNOSTICS
- 13.1.14.1 Business overview
- 13.1.14.2 Products offered
- 13.1.15 BODITECH MED INC.
- 13.1.15.1 Business overview
- 13.1.15.2 Products offered
- 13.1.15.3 Recent developments
- 13.1.15.3.1 Product launches and approvals
- 13.1.15.3.2 Deals
- 13.1.15.3.3 Expansions
- 13.2 OTHER PLAYERS
- 13.2.1 GRIFOLS, S.A.
- 13.2.2 LIFESCAN IP HOLDINGS, LLC
- 13.2.3 PTS DIAGNOSTICS
- 13.2.4 EUROLYSER DIAGNOSTICA GMBH
- 13.2.5 RESPONSE BIOMEDICAL
- 13.2.6 ALFA SCIENTIFIC DESIGNS, INC.
- 13.2.7 BTNX INC.
- 13.2.8 ASCENSIA DIABETES CARE HOLDINGS AG
- 13.2.9 FLUXERGY
- 13.2.10 PRECISION BIOSENSOR, INC.
- 13.2.11 ACON LABORATORIES, INC.
- 13.2.12 MENARINI DIAGNOSTICS S.R.L
- 13.2.13 ORASURE TECHNOLOGIES, INC.
- 13.2.14 MANKIND PHARMA
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
